

Neal L Benowitz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8158694/publications.pdf>

Version: 2024-02-01

364
papers

34,007
citations

3919

88
h-index

4419

172
g-index

368
all docs

368
docs citations

368
times ranked

20748
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Biochemical verification of tobacco use and cessation. <i>Nicotine and Tobacco Research</i> , 2002, 4, 149-159. | 1.4 | 1,670 |
| 2 | Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. <i>Tobacco Control</i> , 2014, 23, 133-139. | 1.8 | 1,324 |
| 3 | Metabolism and Disposition Kinetics of Nicotine. <i>Pharmacological Reviews</i> , 2005, 57, 79-115. | 7.1 | 1,298 |
| 4 | Nicotine Addiction. <i>New England Journal of Medicine</i> , 2010, 362, 2295-2303. | 13.9 | 1,196 |
| 5 | Nicotine Chemistry, Metabolism, Kinetics and Biomarkers. <i>Handbook of Experimental Pharmacology</i> , 2009, , 29-60. | 0.9 | 1,045 |
| 6 | E-Cigarettes. <i>Circulation</i> , 2014, 129, 1972-1986. | 1.6 | 1,031 |
| 7 | Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. <i>Lancet, The</i> , 2016, 387, 2507-2520. | 6.3 | 929 |
| 8 | Pharmacology of Nicotine: Addiction, Smoking-Induced Disease, and Therapeutics. <i>Annual Review of Pharmacology and Toxicology</i> , 2009, 49, 57-71. | 4.2 | 664 |
| 9 | Drug Interactions with Tobacco Smoking. <i>Clinical Pharmacokinetics</i> , 1999, 36, 425-438. | 1.6 | 562 |
| 10 | Nicotine absorption and cardiovascular effects with smokeless tobacco use: Comparison with cigarettes and nicotine gum. <i>Clinical Pharmacology and Therapeutics</i> , 1988, 44, 23-28. | 2.3 | 544 |
| 11 | Optimal Serum Cotinine Levels for Distinguishing Cigarette Smokers and Nonsmokers Within Different Racial/Ethnic Groups in the United States Between 1999 and 2004. <i>American Journal of Epidemiology</i> , 2009, 169, 236-248. | 1.6 | 544 |
| 12 | Establishing a Nicotine Threshold for Addiction – The Implications for Tobacco Regulation. <i>New England Journal of Medicine</i> , 1994, 331, 123-125. | 13.9 | 459 |
| 13 | Electronic cigarettes: review of use, content, safety, effects on smokers and potential for harm and benefit. <i>Addiction</i> , 2014, 109, 1801-1810. | 1.7 | 446 |
| 14 | Cotinine disposition and effects. <i>Clinical Pharmacology and Therapeutics</i> , 1983, 34, 604-611. | 2.3 | 434 |
| 15 | Improved gas chromatographic method for the determination of nicotine and cotinine in biologic fluids. <i>Biomedical Applications</i> , 1981, 222, 61-70. | 1.7 | 426 |
| 16 | Metabolism of nicotine to cotinine studied by a dual stable isotope method. <i>Clinical Pharmacology and Therapeutics</i> , 1994, 56, 483-493. | 2.3 | 415 |
| 17 | Female sex and oral contraceptive use accelerate nicotine metabolism. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 79, 480-488. | 2.3 | 396 |
| 18 | Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity*1. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 64-72. | 2.3 | 366 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Electronic Cigarettes. <i>Circulation</i> , 2014, 130, 1418-1436. | 1.6 | 348 |
| 20 | Efficacy and Safety of Varenicline for Smoking Cessation in Patients With Cardiovascular Disease. <i>Circulation</i> , 2010, 121, 221-229. | 1.6 | 336 |
| 21 | Cigarette smoking and cardiovascular disease: pathophysiology and implications for treatment. <i>Progress in Cardiovascular Diseases</i> , 2003, 46, 91-111. | 1.6 | 335 |
| 22 | Biochemical Verification of Tobacco Use and Abstinence: 2019 Update. <i>Nicotine and Tobacco Research</i> , 2020, 22, 1086-1097. | 1.4 | 325 |
| 23 | Randomized Trial of Reduced-Nicotine Standards for Cigarettes. <i>New England Journal of Medicine</i> , 2015, 373, 1340-1349. | 13.9 | 312 |
| 24 | Cardiovascular toxicity of nicotine: Implications for electronic cigarette use. <i>Trends in Cardiovascular Medicine</i> , 2016, 26, 515-523. | 2.3 | 301 |
| 25 | Risks and Benefits of Nicotine to Aid Smoking Cessation in Pregnancy. <i>Drug Safety</i> , 2001, 24, 277-322. | 1.4 | 286 |
| 26 | Circadian blood nicotine concentrations during cigarette smoking. <i>Clinical Pharmacology and Therapeutics</i> , 1982, 32, 758-764. | 2.3 | 272 |
| 27 | Neurobiology of Nicotine Addiction: Implications for Smoking Cessation Treatment. <i>American Journal of Medicine</i> , 2008, 121, S3-S10. | 0.6 | 267 |
| 28 | Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. <i>Lancet Respiratory Medicine</i> , 2015, 3, 131-138. | 5.2 | 247 |
| 29 | Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 79, 600-608. | 2.3 | 242 |
| 30 | Exposure to Nicotine and Selected Toxicants in Cigarette Smokers Who Switched to Electronic Cigarettes: A Longitudinal Within-Subjects Observational Study. <i>Nicotine and Tobacco Research</i> , 2017, 19, 160-167. | 1.4 | 234 |
| 31 | Selected ion monitoring method for determination of nicotine, cotinine and deuterium-labeled analogs: Absence of an isotope effect in the clearance of (S)-nicotine- ^3H , ^3H - d_2 in humans. <i>Biological Mass Spectrometry</i> , 1991, 20, 247-252. | 0.5 | 219 |
| 32 | 2018 ACC Expert Consensus Decision Pathway on Tobacco Cessation Treatment. <i>Journal of the American College of Cardiology</i> , 2018, 72, 3332-3365. | 1.2 | 219 |
| 33 | Clinical Pharmacokinetics of Lignocaine. <i>Clinical Pharmacokinetics</i> , 1978, 3, 177-201. | 1.6 | 213 |
| 34 | Nicotine and cotinine elimination pharmacokinetics in smokers and nonsmokers. <i>Clinical Pharmacology and Therapeutics</i> , 1993, 53, 316-323. | 2.3 | 213 |
| 35 | Nicotine delivery, retention and pharmacokinetics from various electronic cigarettes. <i>Addiction</i> , 2016, 111, 535-544. | 1.7 | 204 |
| 36 | Lidocaine disposition kinetics in monkey and man; I. Prediction by a perfusion model. <i>Clinical Pharmacology and Therapeutics</i> , 1974, 16, 87-98. | 2.3 | 203 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Arteriovenous differences in plasma concentration of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray, and intravenous nicotine*. <i>Clinical Pharmacology and Therapeutics</i> , 1997, 62, 453-463. | 2.3 | 203 |
| 38 | Mentholated Cigarette Smoking Inhibits Nicotine Metabolism. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 310, 1208-1215. | 1.3 | 201 |
| 39 | Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: A validation study. <i>Pharmacology Biochemistry and Behavior</i> , 2009, 92, 6-11. | 1.3 | 200 |
| 40 | Cardiovascular effects of electronic cigarettes. <i>Nature Reviews Cardiology</i> , 2017, 14, 447-456. | 6.1 | 197 |
| 41 | Slower Metabolism and Reduced Intake of Nicotine From Cigarette Smoking in Chinese-Americans. <i>Journal of the National Cancer Institute</i> , 2002, 94, 108-115. | 3.0 | 192 |
| 42 | The Past, Present, and Future of Nicotine Addiction Therapy. <i>Annual Review of Medicine</i> , 2016, 67, 467-486. | 5.0 | 192 |
| 43 | Nicotine Blood Levels and Subjective Craving for Cigarettes. <i>Pharmacology Biochemistry and Behavior</i> , 2000, 66, 553-558. | 1.3 | 190 |
| 44 | E-cigarette use results in suppression of immune and inflammatory-response genes in nasal epithelial cells similar to cigarette smoke. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2016, 311, L135-L144. | 1.3 | 187 |
| 45 | Determination of the nicotine metabolites cotinine and trans-3-hydroxycotinine in biologic fluids of smokers and non-smokers using liquid chromatography-tandem mass spectrometry: Biomarkers for tobacco smoke exposure and for phenotyping cytochrome P450 2A6 activity. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2011, 879, 267-276. | 1.2 | 185 |
| 46 | CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 457-467. | 2.3 | 184 |
| 47 | Clinical Pharmacology and Toxicology of Cocaine. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1993, 72, 3-12. | 0.0 | 179 |
| 48 | Thirdhand Smoke: New Evidence, Challenges, and Future Directions. <i>Chemical Research in Toxicology</i> , 2017, 30, 270-294. | 1.7 | 178 |
| 49 | Cardiovascular Effects of Exposure to Cigarette Smoke and Electronic Cigarettes. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1378-1391. | 1.2 | 164 |
| 50 | Determinants of nicotine intake while chewing nicotine polacrilex gum. <i>Clinical Pharmacology and Therapeutics</i> , 1987, 41, 467-473. | 2.3 | 163 |
| 51 | Nicotine metabolite ratio as a predictor of cigarette consumption. <i>Nicotine and Tobacco Research</i> , 2003, 5, 621-624. | 1.4 | 163 |
| 52 | The Regulatory Challenge of Electronic Cigarettes. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 685. | 3.8 | 150 |
| 53 | Balancing Consideration of the Risks and Benefits of E-Cigarettes. <i>American Journal of Public Health</i> , 2021, 111, 1661-1672. | 1.5 | 150 |
| 54 | Cardiovascular effects of prolonged delta-9-tetrahydrocannabinol ingestion. <i>Clinical Pharmacology and Therapeutics</i> , 1975, 18, 287-297. | 2.3 | 142 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Sympathomimetic effects of paraxanthine and caffeine in humans*. Clinical Pharmacology and Therapeutics, 1995, 58, 684-691. | 2.3 | 139 |
| 56 | Clonidine for smoking cessation. The Cochrane Library, 2004, , CD000058. | 1.5 | 138 |
| 57 | Reducing the nicotine content to make cigarettes less addictive. Tobacco Control, 2013, 22, i14-i17. | 1.8 | 136 |
| 58 | Nicotine Replacement Therapy. Drugs, 1993, 45, 157-170. | 4.9 | 135 |
| 59 | IQOS: examination of Philip Morris International's claim of reduced exposure. Tobacco Control, 2018, 27, s30-s36. | 1.8 | 135 |
| 60 | Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome. Clinical Pharmacology and Therapeutics, 1993, 53, 529-535. | 2.3 | 132 |
| 61 | Smoking Behavior and Exposure to Tobacco Toxicants during 6 Months of Smoking Progressively Reduced Nicotine Content Cigarettes. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 761-769. | 1.1 | 132 |
| 62 | Elimination Kinetics of the Tobacco-Specific Biomarker and Lung Carcinogen 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanol. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 3421-3425. | 1.1 | 131 |
| 63 | Nicotine and Carcinogen Exposure with Smoking of Progressively Reduced Nicotine Content Cigarette. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 2479-2485. | 1.1 | 130 |
| 64 | Comparison of Urine Cotinine and the Tobacco-Specific Nitrosamine Metabolite 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanol (NNAL) and Their Ratio to Discriminate Active From Passive Smoking. Nicotine and Tobacco Research, 2011, 13, 202-208. | 1.4 | 129 |
| 65 | Adolescent Exposure to Toxic Volatile Organic Chemicals From E-Cigarettes. Pediatrics, 2018, 141, . | 1.0 | 129 |
| 66 | Comparison of Nicotine and Carcinogen Exposure with Water Pipe and Cigarette Smoking. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 765-772. | 1.1 | 128 |
| 67 | Cigarette Smoke Toxins Deposited on Surfaces: Implications for Human Health. PLoS ONE, 2014, 9, e86391. | 1.1 | 125 |
| 68 | Pharmacokinetics in Patients with Cardiac Failure. Clinical Pharmacokinetics, 1976, 1, 389-405. | 1.6 | 121 |
| 69 | Stable isotope studies of nicotine kinetics and bioavailability. Clinical Pharmacology and Therapeutics, 1991, 49, 270-277. | 2.3 | 119 |
| 70 | Nicotine, Carbon Monoxide, and Carcinogen Exposure after a Single Use of a Water Pipe. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2345-2353. | 1.1 | 113 |
| 71 | Effect of Immediate vs Gradual Reduction in Nicotine Content of Cigarettes on Biomarkers of Smoke Exposure. JAMA - Journal of the American Medical Association, 2018, 320, 880. | 3.8 | 113 |
| 72 | Current advances in research in treatment and recovery: Nicotine addiction. Science Advances, 2019, 5, eaay9763. | 4.7 | 112 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Pharmacotherapy for smoking cessation during pregnancy. <i>Nicotine and Tobacco Research</i> , 2004, 6, 189-202. | 1.4 | 109 |
| 74 | Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers. <i>JAMA Internal Medicine</i> , 2018, 178, 622. | 2.6 | 108 |
| 75 | Lidocaine disposition kinetics in monkey and man; II. Effects of hemorrhage and sympathomimetic drug administration. <i>Clinical Pharmacology and Therapeutics</i> , 1974, 16, 99-109. | 2.3 | 106 |
| 76 | Changes in rate and pattern of caffeine metabolism after cigarette abstinence. <i>Clinical Pharmacology and Therapeutics</i> , 1988, 43, 488-491. | 2.3 | 105 |
| 77 | Racial Differences in the Relationship Between Number of Cigarettes Smoked and Nicotine and Carcinogen Exposure. <i>Nicotine and Tobacco Research</i> , 2011, 13, 772-783. | 1.4 | 105 |
| 78 | Gender differences in the pharmacology of nicotine addiction. <i>Addiction Biology</i> , 1998, 3, 383-404. | 1.4 | 104 |
| 79 | Subpicogram per Milliliter Determination of the Tobacco-Specific Carcinogen Metabolite 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol in Human Urine Using Liquid Chromatography~Tandem Mass Spectrometry. <i>Analytical Chemistry</i> , 2008, 80, 8115-8121. | 3.2 | 104 |
| 80 | Nicotine intake and dose response when smoking reduced~nicotine content cigarettes. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 703-714. | 2.3 | 101 |
| 81 | Nicotine Metabolite Ratio Predicts Smoking Topography and Carcinogen Biomarker Level. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 234-238. | 1.1 | 101 |
| 82 | Dose-dependency of caffeine metabolism with repeated dosing. <i>Clinical Pharmacology and Therapeutics</i> , 1990, 48, 277-285. | 2.3 | 100 |
| 83 | Cardiovascular Effects of Nasal and Transdermal Nicotine and Cigarette Smoking. <i>Hypertension</i> , 2002, 39, 1107-1112. | 1.3 | 100 |
| 84 | Reproducibility of the Nicotine Metabolite Ratio in Cigarette Smokers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1105-1114. | 1.1 | 96 |
| 85 | Biomarkers of exposure to new and emerging tobacco delivery products. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2017, 313, L425-L452. | 1.3 | 95 |
| 86 | The Effect of Cigarette Smoking on Penile Erection. <i>Journal of Urology</i> , 1987, 138, 438-441. | 0.2 | 94 |
| 87 | Cardiovascular effects of intravenous delta~tetrahydrocannabinol: Autonomic nervous mechanisms. <i>Clinical Pharmacology and Therapeutics</i> , 1979, 25, 440-446. | 2.3 | 93 |
| 88 | Nicotine metabolism and elimination kinetics in newborns. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 67, 458-465. | 2.3 | 91 |
| 89 | Reduced Tar, Nicotine, and Carbon Monoxide Exposure While Smoking Ultralow- but Not Low-Yield Cigarettes. <i>JAMA - Journal of the American Medical Association</i> , 1986, 256, 241. | 3.8 | 88 |
| 90 | Carcinogen Exposure during Short-term Switching from Regular to "Light" Cigarettes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 1376-1383. | 1.1 | 88 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Pharmacokinetic-pharmacodynamic modeling of caffeine: Tolerance to pressor effects. <i>Clinical Pharmacology and Therapeutics</i> , 1993, 53, 6-14. | 2.3 | 86 |
| 92 | Urine nicotine metabolite concentrations in relation to plasma cotinine during low-level nicotine exposure. <i>Nicotine and Tobacco Research</i> , 2009, 11, 954-960. | 1.4 | 86 |
| 93 | Effects of cigarette smoking and carbon monoxide on chlorzoxazone and caffeine metabolism. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 74, 468-474. | 2.3 | 85 |
| 94 | Emissions from Electronic Cigarettes: Assessing Vapers' Intake of Toxic Compounds, Secondhand Exposures, and the Associated Health Impacts. <i>Environmental Science & Technology</i> , 2017, 51, 9271-9279. | 4.6 | 85 |
| 95 | Characterization of Nicotine Salts in 23 Electronic Cigarette Refill Liquids. <i>Nicotine and Tobacco Research</i> , 2020, 22, 1239-1243. | 1.4 | 85 |
| 96 | Impact of e-liquid flavors on nicotine intake and pharmacology of e-cigarettes. <i>Drug and Alcohol Dependence</i> , 2017, 178, 391-398. | 1.6 | 83 |
| 97 | Poisoning Due to Class IA Antiarrhythmic Drugs Quinidine, Procainamide and Disopyramide. <i>Drug Safety</i> , 1990, 5, 393-420. | 1.4 | 79 |
| 98 | Dose-related cardiovascular and endocrine effects of transdermal nicotine*. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 64, 87-95. | 2.3 | 79 |
| 99 | Cigarette Filter Ventilation and its Relationship to Increasing Rates of Lung Adenocarcinoma. <i>Journal of the National Cancer Institute</i> , 2017, 109, . | 3.0 | 79 |
| 100 | Prevalence of Smoking Assessed Biochemically in an Urban Public Hospital: A Rationale for Routine Cotinine Screening. <i>American Journal of Epidemiology</i> , 2009, 170, 885-891. | 1.6 | 78 |
| 101 | Stable isotope method for studying transdermal drug absorption: The nicotine patch. <i>Clinical Pharmacology and Therapeutics</i> , 1991, 50, 286-293. | 2.3 | 77 |
| 102 | Disposition kinetics and effects of menthol. <i>Clinical Pharmacology and Therapeutics</i> , 1999, 66, 128-135. | 2.3 | 77 |
| 103 | The Ability of Plasma Cotinine to Predict Nicotine and Carcinogen Exposure is Altered by Differences in CYP2A6: the Influence of Genetics, Race, and Sex. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 708-718. | 1.1 | 77 |
| 104 | Urine Nicotine Metabolites and Smoking Behavior in a Multiracial/Multiethnic National Sample of Young Adults. <i>American Journal of Epidemiology</i> , 2007, 165, 901-910. | 1.6 | 76 |
| 105 | Bupropion for Smoking Cessation in African American Light Smokers: A Randomized Controlled Trial. <i>Journal of the National Cancer Institute</i> , 2012, 104, 290-298. | 3.0 | 74 |
| 106 | Emerging Nicotine Delivery Products. Implications for Public Health. <i>Annals of the American Thoracic Society</i> , 2014, 11, 231-235. | 1.5 | 74 |
| 107 | Genetic and environmental influences on the ratio of 3-hydroxycotinine to cotinine in plasma and urine. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 388-398. | 0.7 | 72 |
| 108 | Nicotine Delivery and Vaping Behavior during <i>ad libitum</i> E-cigarette Access. <i>Tobacco Regulatory Science (discontinued)</i> , 2016, 2, 363-376. | 0.2 | 71 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Poisoning Due to Calcium Antagonists. <i>Drug Safety</i> , 1991, 6, 408-430. | 1.4 | 70 |
| 110 | Nicotine and Carcinogen Exposure after Water Pipe Smoking in Hookah Bars. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1055-1066. | 1.1 | 70 |
| 111 | Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influence. <i>Pharmacogenetics and Genomics</i> , 2005, 15, 115-125. | 0.7 | 68 |
| 112 | Cytisine for smoking cessation: A research agenda. <i>Drug and Alcohol Dependence</i> , 2008, 92, 3-8. | 1.6 | 68 |
| 113 | Neuropsychiatric Safety and Efficacy of Varenicline, Bupropion, and Nicotine Patch in Smokers With Psychotic, Anxiety, and Mood Disorders in the EAGLES Trial. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 108-116. | 0.7 | 67 |
| 114 | Pharmacokinetics of Haemoperfusion for Drug Overdose. <i>Clinical Pharmacokinetics</i> , 1979, 4, 329-354. | 1.6 | 66 |
| 115 | Nicotine Metabolite Ratio (3-Hydroxycotinine/Cotinine) in Plasma and Urine by Different Analytical Methods and Laboratories: Implications for Clinical Implementation. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1239-1246. | 1.1 | 65 |
| 116 | Dietary supplement adverse events: Report of a one-year poison center surveillance project. <i>Journal of Medical Toxicology</i> , 2008, 4, 84-92. | 0.8 | 64 |
| 117 | Cytisine for nicotine addiction treatment: a review of pharmacology, therapeutics and an update of clinical trial evidence for smoking cessation. <i>Addiction</i> , 2019, 114, 1951-1969. | 1.7 | 63 |
| 118 | Metabolic and psychophysiologic studies of cannabidiol-hexobarbital interaction. <i>Clinical Pharmacology and Therapeutics</i> , 1980, 28, 115-120. | 2.3 | 62 |
| 119 | Effects of cigarette smoking and carbon monoxide on nicotine and cotinine metabolism. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 67, 653-659. | 2.3 | 61 |
| 120 | Reduced nicotine product standards for combustible tobacco: Building an empirical basis for effective regulation. <i>Preventive Medicine</i> , 2014, 68, 17-22. | 1.6 | 61 |
| 121 | Is Clonidine an Effective Smoking Cessation Therapy?. <i>Drugs</i> , 1995, 50, 197-207. | 4.9 | 60 |
| 122 | Within-Subject Variation of the Salivary 3HC/COT Ratio in Regular Daily Smokers: Prospects for Estimating CYP2A6 Enzyme Activity in Large-Scale Surveys of Nicotine Metabolic Rate. <i>Journal of Analytical Toxicology</i> , 2006, 30, 386-389. | 1.7 | 60 |
| 123 | Nicotine delivery and cigarette equivalents from vaping a JUULpod. <i>Tobacco Control</i> , 2022, 31, e88-e93. | 1.8 | 60 |
| 124 | Factors associated with the efficacy of smoking cessation treatments and predictors of smoking abstinence in EAGLES. <i>Addiction</i> , 2018, 113, 1507-1516. | 1.7 | 58 |
| 125 | Dual Users Compared to Smokers: Demographics, Dependence, and Biomarkers. <i>Nicotine and Tobacco Research</i> , 2019, 21, 1279-1284. | 1.4 | 58 |
| 126 | Anabasine and anatabine as biomarkers for tobacco use during nicotine replacement therapy. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2002, 11, 1668-73. | 1.1 | 58 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | Children's Exposure to Secondhand and Thirdhand Smoke Carcinogens and Toxicants in Homes of Hookah Smokers. <i>Nicotine and Tobacco Research</i> , 2014, 16, 961-975. | 1.4 | 57 |
| 128 | Pharmacokinetics of Drug Overdose. <i>Clinical Pharmacokinetics</i> , 1981, 6, 161-192. | 1.6 | 56 |
| 129 | Rate of Nicotine Metabolism and Withdrawal Symptoms in Adolescent Light Smokers. <i>Pediatrics</i> , 2008, 122, e643-e647. | 1.0 | 56 |
| 130 | Impact of Smoking on Cardiovascular Events in Patients With Coronary Disease Receiving Contemporary Medical Therapy (from the Treating to New Targets [TNT] and the Incremental Decrease in Total Cardiovascular Risk by Everlasting Therapy [INTERVAL] Studies). <i>Journal of the American College of Cardiology</i> , 2010, 55, 107, 145-150. | 0.7 | 56 |
| 131 | Prevention and Treatment of Tobacco Use. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1030-1045. | 1.2 | 56 |
| 132 | Deficient C-oxidation of nicotine*. <i>Clinical Pharmacology and Therapeutics</i> , 1995, 57, 590-594. | 2.3 | 55 |
| 133 | Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 135-141. | 0.7 | 55 |
| 134 | E-cigarette Dependence Measures in Dual Users: Reliability and Relations With Dependence Criteria and E-cigarette Cessation. <i>Nicotine and Tobacco Research</i> , 2020, 22, 756-763. | 1.4 | 55 |
| 135 | Effect of Pod e-Cigarettes vs Cigarettes on Carcinogen Exposure Among African American and Latinx Smokers. <i>JAMA Network Open</i> , 2020, 3, e2026324. | 2.8 | 55 |
| 136 | Cardiovascular and Metabolic Considerations in Prolonged Cannabinoid Administration in Man. <i>Journal of Clinical Pharmacology</i> , 1981, 21, 214S-223S. | 1.0 | 54 |
| 137 | Tobacco Consumption and Toxicant Exposure of Cigarette Smokers Using Electronic Cigarettes. <i>Nicotine and Tobacco Research</i> , 2018, 20, ntw333. | 1.4 | 54 |
| 138 | Comparison of Systemic Exposure to Toxic and/or Carcinogenic Volatile Organic Compounds (VOC) during Vaping, Smoking, and Abstinence. <i>Cancer Prevention Research</i> , 2020, 13, 153-162. | 0.7 | 54 |
| 139 | Influence of tobacco abstinence on the disposition kinetics and effects of nicotine. <i>Clinical Pharmacology and Therapeutics</i> , 1987, 41, 474-479. | 2.3 | 53 |
| 140 | Thirdhand smoke contamination in hospital settings: assessing exposure risk for vulnerable paediatric patients: Table A1. <i>Tobacco Control</i> , 2016, 25, 619-623. | 1.8 | 53 |
| 141 | Impact of e-liquid flavors on e-cigarette vaping behavior. <i>Drug and Alcohol Dependence</i> , 2018, 189, 42-48. | 1.6 | 53 |
| 142 | Changes in Use Patterns Over 1 Year Among Smokers and Dual Users of Combustible and Electronic Cigarettes. <i>Nicotine and Tobacco Research</i> , 2020, 22, 672-680. | 1.4 | 53 |
| 143 | Compensatory Smoking from Gradual and Immediate Reduction in Cigarette Nicotine Content. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 472-476. | 1.1 | 52 |
| 144 | Factors That Explain Differences in Abstinence Between Black and White Smokers: A Prospective Intervention Study. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1078-1087. | 3.0 | 52 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | Racial differences in the relationship between rate of nicotine metabolism and nicotine intake from cigarette smoking. <i>Pharmacology Biochemistry and Behavior</i> , 2016, 148, 1-7. | 1.3 | 51 |
| 146 | Effects of delta-9-tetrahydrocannabinol on drug distribution and metabolism Antipyrine, pentobarbital, and ethanol. <i>Clinical Pharmacology and Therapeutics</i> , 1977, 22, 259-268. | 2.3 | 50 |
| 147 | Simultaneous determination of mecamylamine, nicotine, and cotinine in plasma by gas chromatography-mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2000, 23, 653-661. | 1.4 | 50 |
| 148 | Cotinine effects on nicotine metabolism*. <i>Clinical Pharmacology and Therapeutics</i> , 1997, 61, 649-654. | 2.3 | 49 |
| 149 | Effects of 6-Week Use of Reduced-Nicotine Content Cigarettes in Smokers With and Without Elevated Depressive Symptoms. <i>Nicotine and Tobacco Research</i> , 2017, 19, 59-67. | 1.4 | 49 |
| 150 | Presystemic metabolism of meperidine to normeperidine in normal and cirrhotic subjects. <i>Clinical Pharmacology and Therapeutics</i> , 1981, 30, 183-188. | 2.3 | 48 |
| 151 | Mouth versus deep airways absorption of nicotine in cigarette smokers. <i>Pharmacology Biochemistry and Behavior</i> , 1986, 25, 1181-1184. | 1.3 | 48 |
| 152 | Prolonged absorption with development of tolerance to toxic effects after cutaneous exposure to nicotine. <i>Clinical Pharmacology and Therapeutics</i> , 1987, 42, 119-120. | 2.3 | 48 |
| 153 | A Comparison of Nicotine Biomarkers and Smoking Patterns in Daily and Nondaily Smokers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1264-1272. | 1.1 | 48 |
| 154 | Cardiovascular Effects of Hookah Smoking: Potential Implications for Cardiovascular Risk. <i>Nicotine and Tobacco Research</i> , 2019, 21, 1151-1161. | 1.4 | 47 |
| 155 | Intravenous nicotine retards transdermal absorption of nicotine: Evidence of blood flowâ€“limited percutaneous absorption. <i>Clinical Pharmacology and Therapeutics</i> , 1992, 52, 223-230. | 2.3 | 46 |
| 156 | Estimation of Nicotine Dose after Low-level Exposure Using Plasma and Urine Nicotine Metabolites. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 1160-1166. | 1.1 | 46 |
| 157 | Individual differences in nicotine intake per cigarette. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2003, 12, 468-71. | 1.1 | 46 |
| 158 | Propranolol antagonism of phenylpropanolamine-induced hypertension. <i>Clinical Pharmacology and Therapeutics</i> , 1985, 37, 488-494. | 2.3 | 45 |
| 159 | Chronopharmacokinetics of nicotine*. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 60, 385-395. | 2.3 | 45 |
| 160 | Alaska Native smokers and smokeless tobacco users with slower CYP2A6 activity have lower tobacco consumption, lower tobacco-specific nitrosamine exposure and lower tobacco-specific nitrosamine bioactivation. <i>Carcinogenesis</i> , 2013, 34, 93-101. | 1.3 | 45 |
| 161 | Genomeâ€“wide association study of a nicotine metabolism biomarker in African American smokers: impact of chromosome 19 genetic influences. <i>Addiction</i> , 2018, 113, 509-523. | 1.7 | 45 |
| 162 | Evaluating the temporal relationships between withdrawal symptoms and smoking relapse.. <i>Psychology of Addictive Behaviors</i> , 2019, 33, 105-116. | 1.4 | 45 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 163 | The Benefits of Stopping Smoking and the Role of Nicotine Replacement Therapy in Older Patients. <i>Drugs and Aging</i> , 1996, 9, 8-23. | 1.3 | 44 |
| 164 | Estimations and predictors of non-compliance in switchers to reduced nicotine content cigarettes. <i>Addiction</i> , 2016, 111, 2208-2216. | 1.7 | 44 |
| 165 | Thirdhand Smoke: State of the Science and a Call for Policy Expansion. <i>Public Health Reports</i> , 2016, 131, 233-238. | 1.3 | 43 |
| 166 | Exposure to polycyclic aromatic hydrocarbons and volatile organic compounds among recently pregnant rural Guatemalan women cooking and heating with solid fuels. <i>International Journal of Hygiene and Environmental Health</i> , 2017, 220, 726-735. | 2.1 | 42 |
| 167 | JUUL electronic cigarettes: Nicotine exposure and the user experience. <i>Drug and Alcohol Dependence</i> , 2019, 203, 83-87. | 1.6 | 42 |
| 168 | Lack of effect of diazepam on methadone metabolism in methadone-maintained addicts. <i>Clinical Pharmacology and Therapeutics</i> , 1982, 31, 139-143. | 2.3 | 41 |
| 169 | Cytisine, the world's oldest smoking cessation aid. <i>BMJ, The</i> , 2013, 347, f5198-f5198. | 3.0 | 41 |
| 170 | Reduced nicotine content cigarettes, e-cigarettes and the cigarette end game. <i>Addiction</i> , 2017, 112, 6-7. | 1.7 | 41 |
| 171 | Comparison of Urine 4-(Methylnitrosamino)-1-(3)Pyridyl-1-Butanol and Cotinine for Assessment of Active and Passive Smoke Exposure in Urban Adolescents. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 254-261. | 1.1 | 41 |
| 172 | Methadone-Disulfiram Interaction During Methadone Maintenance. <i>Journal of Clinical Pharmacology</i> , 1980, 20, 506-513. | 1.0 | 40 |
| 173 | Lack of Associations of CHRNA5-A3-B4 Genetic Variants with Smoking Cessation Treatment Outcomes in Caucasian Smokers despite Associations with Baseline Smoking. <i>PLoS ONE</i> , 2015, 10, e0128109. | 1.1 | 40 |
| 174 | Validity of self-reported adult secondhand smoke exposure. <i>Tobacco Control</i> , 2015, 24, 48-53. | 1.8 | 40 |
| 175 | Tobacco Alkaloids and Tobacco-Specific Nitrosamines in Dust from Homes of Smokeless Tobacco Users, Active Smokers, and Nontobacco Users. <i>Chemical Research in Toxicology</i> , 2015, 28, 1007-1014. | 1.7 | 40 |
| 176 | Pharmacodynamics of nicotine: implications for rational treatment of nicotine addiction. <i>Addiction</i> , 1991, 86, 495-499. | 1.7 | 39 |
| 177 | Non-Nicotine Pharmacotherapy for Smoking Cessation. <i>CNS Drugs</i> , 2000, 13, 265-285. | 2.7 | 39 |
| 178 | CYP2A6 and CYP2B6 genetic variation and its association with nicotine metabolism in South Western Alaska Native people. <i>Pharmacogenetics and Genomics</i> , 2012, 22, 429-440. | 0.7 | 39 |
| 179 | Variation in Trans-3-Hydroxycotinine Glucuronidation Does Not Alter the Nicotine Metabolite Ratio or Nicotine Intake. <i>PLoS ONE</i> , 2013, 8, e70938. | 1.1 | 39 |
| 180 | Urine Menthol as a Biomarker of Mentholated Cigarette Smoking. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 3013-3019. | 1.1 | 38 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 181 | Urine Cotinine Underestimates Exposure to the Tobacco-Derived Lung Carcinogen 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone in Passive Compared with Active Smokers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2795-2800. | 1.1 | 37 |
| 182 | Nicotelline: A Proposed Biomarker and Environmental Tracer for Particulate Matter Derived from Tobacco Smoke. <i>Chemical Research in Toxicology</i> , 2013, 26, 1615-1631. | 1.7 | 37 |
| 183 | Genome-Wide Association of the Laboratory-Based Nicotine Metabolite Ratio in Three Ancestries. <i>Nicotine and Tobacco Research</i> , 2016, 18, 1837-1844. | 1.4 | 37 |
| 184 | Effect of e-cigarette flavors on nicotine delivery and puffing topography: results from a randomized clinical trial of daily smokers. <i>Psychopharmacology</i> , 2020, 237, 491-502. | 1.5 | 37 |
| 185 | Pharmacokinetic Considerations in Understanding Nicotine Dependence. <i>Novartis Foundation Symposium</i> , 1990, 152, 186-209. | 1.2 | 37 |
| 186 | Pharmacokinetic and Pharmacodynamic Considerations in Drug Therapy of Cardiac Emergencies. <i>Clinical Pharmacokinetics</i> , 1984, 9, 273-308. | 1.6 | 36 |
| 187 | Additive cardiovascular effects of nicotine and ethanol. <i>Clinical Pharmacology and Therapeutics</i> , 1986, 40, 420-424. | 2.3 | 36 |
| 188 | Effects of passive smoking on theophylline clearance. <i>Clinical Pharmacology and Therapeutics</i> , 1989, 46, 399-407. | 2.3 | 36 |
| 189 | An Electronic Cigarette Vaping Machine for the Characterization of Aerosol Delivery and Composition. <i>Nicotine and Tobacco Research</i> , 2017, 19, ntw147. | 1.4 | 36 |
| 190 | E-Cigarettes and Cardiopulmonary Health. <i>Function</i> , 2021, 2, zqab004. | 1.1 | 36 |
| 191 | Pharmacoepidemiology of the effect of caffeine on blood pressure. <i>Clinical Pharmacology and Therapeutics</i> , 1990, 47, 57-60. | 2.3 | 35 |
| 192 | Validation of urine caffeine metabolite ratios with use of stable isotope-labeled caffeine clearance*. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 59, 284-296. | 2.3 | 35 |
| 193 | Racial differences in the relationship between tobacco dependence and nicotine and carcinogen exposure. <i>Addiction</i> , 2013, 108, 607-617. | 1.7 | 35 |
| 194 | Intake of Toxic and Carcinogenic Volatile Organic Compounds from Secondhand Smoke in Motor Vehicles. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2774-2782. | 1.1 | 35 |
| 195 | The Threat of Menthol Cigarettes to U.S. Public Health. <i>New England Journal of Medicine</i> , 2011, 364, 2179-2181. | 13.9 | 34 |
| 196 | Saliva cotinine levels as a function of collection method. <i>Addiction</i> , 1997, 92, 347-351. | 1.7 | 33 |
| 197 | Predictors of cessation in African American light smokers enrolled in a bupropion clinical trial. <i>Addictive Behaviors</i> , 2013, 38, 1796-1803. | 1.7 | 33 |
| 198 | Effect of reducing the nicotine content of cigarettes on cigarette smoking behavior and tobacco smoke toxicant exposure: 2-year follow up. <i>Addiction</i> , 2015, 110, 1667-1675. | 1.7 | 33 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 199 | Urine Metabolites for Estimating Daily Intake of Nicotine From Cigarette Smoking. <i>Nicotine and Tobacco Research</i> , 2020, 22, 288-292. | 1.4 | 33 |
| 200 | Divergent tolerance to metabolic and cardiovascular effects of nicotine in smokers with low and high levels of cigarette consumption. <i>Clinical Pharmacology and Therapeutics</i> , 1994, 56, 55-64. | 2.3 | 32 |
| 201 | Environmental and Drug-Induced Hyperthermia Pathophysiology, Recognition, Management. <i>Emergency Medicine Clinics of North America</i> , 1984, 2, 459-474. | 0.5 | 32 |
| 202 | Measures and predictors of varenicline adherence in the treatment of nicotine dependence. <i>Addictive Behaviors</i> , 2017, 75, 122-129. | 1.7 | 31 |
| 203 | Differences in nicotine intake and effects from electronic and combustible cigarettes among dual users. <i>Addiction</i> , 2020, 115, 757-767. | 1.7 | 31 |
| 204 | Prolonged delta-9-tetrahydrocannabinol ingestion; Effects of sympathomimetic amines and autonomic blockades. <i>Clinical Pharmacology and Therapeutics</i> , 1977, 21, 336-342. | 2.3 | 30 |
| 205 | Synthesis of optically pure deuterium-labelled nicotine, nornicotine and cotinine. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1988, 25, 1117-1128. | 0.5 | 30 |
| 206 | Progressive Commercial Cigarette Yield Reduction: Biochemical Exposure and Behavioral Assessment. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 876-883. | 1.1 | 30 |
| 207 | Disposition kinetics and metabolism of nicotine and cotinine in African American smokers. <i>Pharmacogenetics and Genomics</i> , 2016, 26, 340-350. | 0.7 | 30 |
| 208 | Early exposure to thirdhand cigarette smoke affects body mass and the development of immunity in mice. <i>Scientific Reports</i> , 2017, 7, 41915. | 1.6 | 30 |
| 209 | Whether to push or pull? Nicotine reduction and non-combusted alternatives - Two strategies for reducing smoking and improving public health. <i>Preventive Medicine</i> , 2018, 117, 8-14. | 1.6 | 30 |
| 210 | Short-term early exposure to thirdhand cigarette smoke increases lung cancer incidence in mice. <i>Clinical Science</i> , 2018, 132, 475-488. | 1.8 | 30 |
| 211 | Secondhand smoke exposure and asthma outcomes among African-American and Latino children with asthma. <i>Thorax</i> , 2018, 73, 1041-1048. | 2.7 | 30 |
| 212 | Nicotine and Anatabine Exposure from Very Low Nicotine Content Cigarettes. <i>Tobacco Regulatory Science (discontinued)</i> , 2016, 2, 186-203. | 0.2 | 29 |
| 213 | Effects of stress on circulating nicotine and cotinine levels and in vitro nicotine metabolism in the rat. <i>Psychopharmacology</i> , 1998, 137, 383-390. | 1.5 | 28 |
| 214 | Effects of Nicotine Metabolic Rate on Withdrawal Symptoms and Response to Cigarette Smoking After Abstinence. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 641-651. | 2.3 | 28 |
| 215 | Cigarette Smoking Sensitizes and Desensitizes Impedance-measured ADP-induced Platelet Aggregation in Whole Blood. <i>Thrombosis and Haemostasis</i> , 1995, 74, 730-735. | 1.8 | 28 |
| 216 | Poisoning Due to Class 1B Antiarrhythmic Drugs. <i>Medical Toxicology and Adverse Drug Experience</i> , 1989, 4, 412-428. | 0.8 | 27 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 217 | High Dose Transdermal Nicotine for Fast Metabolizers of Nicotine: A Proof of Concept Placebo-Controlled Trial. <i>Nicotine and Tobacco Research</i> , 2013, 15, 348-354. | 1.4 | 27 |
| 218 | Multiple risk-behavior profiles of smokers with serious mental illness and motivation for change.. <i>Health Psychology</i> , 2014, 33, 1518-1529. | 1.3 | 27 |
| 219 | <i>UGT1A</i> and <i>UGT2B</i> Genetic Variation Alters Nicotine and Nitrosamine Glucuronidation in European and African American Smokers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 94-104. | 1.1 | 27 |
| 220 | Electronic cigarette chemicals transfer from a vape shop to a nearby business in a multiple-tenant retail building. <i>Tobacco Control</i> , 2019, 28, 519-525. | 1.8 | 27 |
| 221 | Urine Cotinine Screening Detect Nearly Ubiquitous Tobacco Smoke Exposure in Urban Adolescents. <i>Nicotine and Tobacco Research</i> , 2017, 19, ntw390. | 1.4 | 26 |
| 222 | Randomized within-subject trial to evaluate smokers' initial perceptions, subjective effects and nicotine delivery across six vaporized nicotine products. <i>Addiction</i> , 2019, 114, 1236-1248. | 1.7 | 26 |
| 223 | Effect of disulfiram on adrenergic function. <i>Clinical Pharmacology and Therapeutics</i> , 1979, 25, 469-475. | 2.3 | 25 |
| 224 | Nicotine Replacement, Topography, and Smoking Phenotypes of E-cigarettes. <i>Tobacco Regulatory Science (discontinued)</i> , 2016, 2, 352-362. | 0.2 | 25 |
| 225 | Evaluation of a weighted genetic risk score for the prediction of biomarkers of CYP2A6 activity. <i>Addiction Biology</i> , 2020, 25, e12741. | 1.4 | 25 |
| 226 | Efficacy and Safety of Pharmacotherapeutic Smoking Cessation Aids in Schizophrenia Spectrum Disorders: Subgroup Analysis of EAGLES. <i>Psychiatric Services</i> , 2021, 72, 7-15. | 1.1 | 25 |
| 227 | Assessment of Racial Differences in Pharmacotherapy Efficacy for Smoking Cessation. <i>JAMA Network Open</i> , 2021, 4, e2032053. | 2.8 | 25 |
| 228 | The effect of liver disease on urine caffeine metabolite ratios*. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 59, 624-635. | 2.3 | 24 |
| 229 | Stability of the Nicotine Metabolite Ratio in Smokers of Progressively Reduced Nicotine Content Cigarettes. <i>Nicotine and Tobacco Research</i> , 2013, 15, 1939-1942. | 1.4 | 24 |
| 230 | Gene Variants in CYP2C19 Are Associated with Altered In Vivo Bupropion Pharmacokinetics but Not Bupropion-Assisted Smoking Cessation Outcomes. <i>Drug Metabolism and Disposition</i> , 2014, 42, 1971-1977. | 1.7 | 24 |
| 231 | Cessation of alcohol consumption decreases rate of nicotine metabolism in male alcohol-dependent smokers. <i>Drug and Alcohol Dependence</i> , 2016, 163, 157-164. | 1.6 | 24 |
| 232 | Orthostatic Hypertension Due to Vascular Adrenergic Hypersensitivity. <i>Hypertension</i> , 1996, 28, 42-46. | 1.3 | 24 |
| 233 | Biochemical Estimation of Noncompliance with Smoking of Very Low Nicotine Content Cigarettes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 331-335. | 1.1 | 23 |
| 234 | The Influence of Puff Characteristics, Nicotine Dependence, and Rate of Nicotine Metabolism on Daily Nicotine Exposure in African American Smokers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 936-943. | 1.1 | 23 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 235 | Tobacco use disorder and cardiovascular health. <i>Addiction</i> , 2022, 117, 1128-1138. | 1.7 | 23 |
| 236 | Exposure to Toxicants Associated With Use and Transitions Between Cigarettes, e-Cigarettes, and No Tobacco. <i>JAMA Network Open</i> , 2022, 5, e2147891. | 2.8 | 22 |
| 237 | Organic Cation Transporter Variation and Response to Smoking Cessation Therapies. <i>Nicotine and Tobacco Research</i> , 2014, 16, 1638-1646. | 1.4 | 21 |
| 238 | Resin hemoperfusion in ethchlorvynol overdose. <i>Clinical Pharmacology and Therapeutics</i> , 1980, 27, 236-242. | 2.3 | 20 |
| 239 | Drug Metabolizing Enzyme and Transporter Gene Variation, Nicotine Metabolism, Prospective Abstinence, and Cigarette Consumption. <i>PLoS ONE</i> , 2015, 10, e0126113. | 1.1 | 20 |
| 240 | Nicotine Dependence, Nicotine Metabolism, and the Extent of Compensation in Response to Reduced Nicotine Content Cigarettes. <i>Nicotine and Tobacco Research</i> , 2015, 17, 1167-1172. | 1.4 | 20 |
| 241 | Association of Reduced Nicotine Content Cigarettes With Smoking Behaviors and Biomarkers of Exposure Among Slow and Fast Nicotine Metabolizers. <i>JAMA Network Open</i> , 2018, 1, e181346. | 2.8 | 20 |
| 242 | Longitudinal stability in cigarette smokers of urinary biomarkers of exposure to the toxicants acrylonitrile and acrolein. <i>PLoS ONE</i> , 2019, 14, e0210104. | 1.1 | 20 |
| 243 | Ubiquitous atmospheric contamination by tobacco smoke: Nicotine and a new marker for tobacco smoke-derived particulate matter, nicotelline. <i>Environment International</i> , 2021, 150, 106417. | 4.8 | 20 |
| 244 | The Impact of Exclusive Use of Very Low Nicotine Cigarettes on Compensatory Smoking: An Inpatient Crossover Clinical Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 880-886. | 1.1 | 20 |
| 245 | Effect of Disulfiram on Cognition, Subjective Response, and Cortical-Related Potentials in Nonalcoholic Subjects. <i>Alcoholism: Clinical and Experimental Research</i> , 1979, 3, 223-229. | 1.4 | 19 |
| 246 | Nicotine-mecamylamine interactions. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 68, 58-66. | 2.3 | 19 |
| 247 | Systemic Nicotine Exposure in Tobacco Harvesters. <i>Archives of Environmental Health</i> , 2001, 56, 257-263. | 0.4 | 19 |
| 248 | Acute Effect of Hookah Smoking on the Human Coronary Microcirculation. <i>American Journal of Cardiology</i> , 2016, 117, 1747-1754. | 0.7 | 19 |
| 249 | High Carbon Monoxide Levels from Charcoal Combustion Mask Acute Endothelial Dysfunction Induced by Hookah (Waterpipe) Smoking in Young Adults. <i>Circulation</i> , 2019, 139, 2215-2224. | 1.6 | 19 |
| 250 | Brain Phenobarbital Uptake during Prolonged Status Epilepticus. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1987, 7, 783-788. | 2.4 | 18 |
| 251 | Effect of UGT2B10, UGT2B17, FMO3, and OCT2 genetic variation on nicotine and cotinine pharmacokinetics and smoking in African Americans. <i>Pharmacogenetics and Genomics</i> , 2017, 27, 143-154. | 0.7 | 18 |
| 252 | Reprint of: Prevention and Treatment of Tobacco Use. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2964-2979. | 1.2 | 18 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 253 | Variation in P450 oxidoreductase (POR) A503V and flavin-containing monooxygenase (FMO)-3 E158K is associated with minor alterations in nicotine metabolism, but does not alter cigarette consumption. <i>Pharmacogenetics and Genomics</i> , 2014, 24, 172-176. | 0.7 | 17 |
| 254 | Reducing nicotine exposure results in weight gain in smokers randomised to very low nicotine content cigarettes. <i>Tobacco Control</i> , 2017, 26, e43-e48. | 1.8 | 17 |
| 255 | Effects of Very Low Nicotine Content Cigarettes on Smoking Behavior and Biomarkers of Exposure in Menthol and Non-menthol Smokers. <i>Nicotine and Tobacco Research</i> , 2019, 21, S63-S72. | 1.4 | 17 |
| 256 | The Role of Compensation in Nicotine Reduction. <i>Nicotine and Tobacco Research</i> , 2019, 21, S16-S18. | 1.4 | 17 |
| 257 | Biomarkers of Exposure for Dual Use of Electronic Cigarettes and Combustible Cigarettes: Nicotelline, NNAL, and Total Nicotine Equivalents. <i>Nicotine and Tobacco Research</i> , 2020, 22, 1107-1113. | 1.4 | 17 |
| 258 | Relationships between the Nicotine Metabolite Ratio and a Panel of Exposure and Effect Biomarkers: Findings from Two Studies of U.S. Commercial Cigarette Smokers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 871-879. | 1.1 | 17 |
| 259 | Clinical Pharmacology of Electronic Nicotine Delivery Systems (ENDS): Implications for Benefits and Risks in the Promotion of the Combusted Tobacco Endgame. <i>Journal of Clinical Pharmacology</i> , 2021, 61, S18-S36. | 1.0 | 17 |
| 260 | The biology of nicotine dependence: From the 1988 Surgeon General's Report to the present and into the future. <i>Nicotine and Tobacco Research</i> , 1999, 1, 159-163. | 1.4 | 16 |
| 261 | <i>CHRNA5</i> genetic variants alter nicotine intake and interact with tobacco use to influence body weight in Alaska Native tobacco users. <i>Addiction</i> , 2013, 108, 1818-1828. | 1.7 | 16 |
| 262 | A Multicenter, Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial of Cytisinicline in Adult Smokers (The ORCA-1 Trial). <i>Nicotine and Tobacco Research</i> , 2021, 23, 1656-1663. | 1.4 | 16 |
| 263 | A clinical trial to examine disparities in quitting between African-American and White adult smokers: Design, accrual, and baseline characteristics. <i>Contemporary Clinical Trials</i> , 2016, 47, 12-21. | 0.8 | 15 |
| 264 | Effect of β -hydroxybutyrate (GHB) on driving as measured by a driving simulator. <i>Psychopharmacology</i> , 2018, 235, 3223-3232. | 1.5 | 15 |
| 265 | Collaborative Method Performance Study of the Measurement of Nicotine, Its Metabolites, and Total Nicotine Equivalents in Human Urine. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 1083-1090. | 1.1 | 15 |
| 266 | Predictors of Neuropsychiatric Adverse Events with Smoking Cessation Medications in the Randomized Controlled EAGLES Trial. <i>Journal of General Internal Medicine</i> , 2019, 34, 862-870. | 1.3 | 15 |
| 267 | Identification and quantification of electronic cigarette exhaled aerosol residue chemicals in field sites. <i>Environmental Research</i> , 2019, 170, 351-358. | 3.7 | 15 |
| 268 | Transferability of Ancestry-specific and Cross-Ancestry CYP2A6 Activity Genetic Risk Scores in African and European Populations. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 975-985. | 2.3 | 15 |
| 269 | Thirdhand smoke associations with the gut microbiomes of infants admitted to a neonatal intensive care unit: An observational study. <i>Environmental Research</i> , 2021, 197, 111180. | 3.7 | 15 |
| 270 | Tobacco-free Nicotine – New Name, Same Scheme?. <i>New England Journal of Medicine</i> , 2021, 385, 2406-2408. | 13.9 | 15 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 271 | Workshop on Problem-Based Learning as a Method for Teaching Clinical Pharmacology and Therapeutics in Medical School. <i>Journal of Clinical Pharmacology</i> , 1992, 32, 779-797. | 1.0 | 14 |
| 272 | How Toxic is Cocaine?. <i>Novartis Foundation Symposium</i> , 1992, 166, 125-148. | 1.2 | 14 |
| 273 | Nicotine Reduction Strategy: State of the science and challenges to tobacco control policy and FDA tobacco product regulation. <i>Preventive Medicine</i> , 2018, 117, 5-7. | 1.6 | 14 |
| 274 | Impact of early nausea on varenicline adherence and smoking cessation. <i>Addiction</i> , 2020, 115, 134-144. | 1.7 | 14 |
| 275 | Twenty-Four-Hour Cardiovascular Effects of Electronic Cigarettes Compared With Cigarette Smoking in Dual Users. <i>Journal of the American Heart Association</i> , 2020, 9, e017317. | 1.6 | 14 |
| 276 | Differences in exposure to toxic and/or carcinogenic volatile organic compounds between Black and White cigarette smokers. <i>Journal of Exposure Science and Environmental Epidemiology</i> , 2021, 31, 211-223. | 1.8 | 14 |
| 277 | Reappraising Choice in Addiction: Novel Conceptualizations and Treatments for Tobacco Use Disorder. <i>Nicotine and Tobacco Research</i> , 2022, 24, 3-9. | 1.4 | 14 |
| 278 | The Healing and Empowering Alaskan Lives Toward Healthy-Hearts (HEALTHH) Project: Study protocol for a randomized controlled trial of an intervention for tobacco use and other cardiovascular risk behaviors for Alaska Native People. <i>Contemporary Clinical Trials</i> , 2018, 71, 40-46. | 0.8 | 13 |
| 279 | Quantitative biochemical screening for marijuana use and concordance with tobacco use in urban adolescents. <i>Drug and Alcohol Dependence</i> , 2019, 205, 107583. | 1.6 | 13 |
| 280 | Biomarker feedback intervention for smoking cessation among Alaska Native pregnant women: Randomized pilot study. <i>Patient Education and Counseling</i> , 2019, 102, 528-535. | 1.0 | 13 |
| 281 | Twenty-four-hour subjective and pharmacological effects of adalbitum electronic and combustible cigarette use among dual users. <i>Addiction</i> , 2020, 115, 1149-1159. | 1.7 | 13 |
| 282 | Diazepam kinetics in acute alcohol withdrawal. <i>Clinical Pharmacology and Therapeutics</i> , 1979, 25, 832-836. | 2.3 | 12 |
| 283 | E-Hookah Versus E-Cigarettes: Findings From Wave 2 of the PATH Study (2014-2015). <i>American Journal of Preventive Medicine</i> , 2019, 57, e163-e173. | 1.6 | 12 |
| 284 | Nicotine Intake, Dependence, and Characteristics of Electronic Cigarette and Dual Users. <i>Tobacco Regulatory Science (discontinued)</i> , 2019, 5, 27-35. | 0.2 | 12 |
| 285 | Secondhand Tobacco Smoke Exposure Among Hospitalized Nonsmokers With Coronary Heart Disease. <i>JAMA Internal Medicine</i> , 2015, 175, 133. | 2.6 | 11 |
| 286 | Sources and Biomarkers of Secondhand Tobacco Smoke Exposure in Urban Adolescents. <i>Academic Pediatrics</i> , 2020, 20, 493-500. | 1.0 | 11 |
| 287 | Mouth-Level Nicotine Intake Estimates from Discarded Filter Butts to Examine Compensatory Smoking in Low Nicotine Cigarettes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 643-649. | 1.1 | 11 |
| 288 | “I actually finally feel like the cigarettes aren’t controlling me.” Interviews with participants smoking very low nicotine content cigarettes during a residential study. <i>Drug and Alcohol Dependence</i> , 2021, 219, 108465. | 1.6 | 11 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 289 | Fetal Exposure to Carcinogens With Tobacco Use in Pregnancy: Phase 1 MAW Study Findings. <i>Nicotine and Tobacco Research</i> , 2016, 18, 2162-2168. | 1.4 | 10 |
| 290 | Longitudinal stability in cigarette smokers of urinary eicosanoid biomarkers of oxidative damage and inflammation. <i>PLoS ONE</i> , 2019, 14, e0215853. | 1.1 | 10 |
| 291 | Effects of reduced nicotine content cigarettes on individual withdrawal symptoms over time and during abstinence.. <i>Experimental and Clinical Psychopharmacology</i> , 2018, 26, 223-232. | 1.3 | 10 |
| 292 | The Central Role of pH in the Clinical Pharmacology of Nicotine: Implications for Abuse Liability, Cigarette Harm Reduction and FDA Regulation. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 1004-1006. | 2.3 | 10 |
| 293 | Birthing of clinical pharmacologists*. <i>Clinical Pharmacology and Therapeutics</i> , 1997, 62, 587-591. | 2.3 | 9 |
| 294 | The Use of Hemodialysis and Hemoperfusion in the Treatment of Theophylline Intoxication. <i>Seminars in Dialysis</i> , 1993, 6, 243-252. | 0.7 | 9 |
| 295 | Different profiles of carcinogen exposure in Chinese compared with US cigarette smokers. <i>Tobacco Control</i> , 2015, 24, e258-e263. | 1.8 | 9 |
| 296 | Seizures After Vaping Nicotine in Youth: A Canary or a Red Herring?. <i>Journal of Adolescent Health</i> , 2020, 66, 1-2. | 1.2 | 9 |
| 297 | Cigarette Smoke Exposure and Acute Respiratory Distress Syndrome in Sepsis: Epidemiology, Clinical Features, and Biologic Markers. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 927-935. | 2.5 | 9 |
| 298 | Effect of Varenicline Added to Counseling on Smoking Cessation Among African American Daily Smokers. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 2201. | 3.8 | 9 |
| 299 | Carbon monoxide, cigarette smoking and CYP2E1 activity. <i>Clinical Pharmacology and Therapeutics</i> , 1999, 65, 154-154. | 2.3 | 8 |
| 300 | Nicotine Addiction: Mechanisms and Consequences. <i>International Journal of Mental Health</i> , 2011, 40, 22-38. | 0.5 | 8 |
| 301 | Comprehensive Parentâ€™Metabolite PBPK/PD Modeling Insights into Nicotine Replacement Therapy Strategies. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1119-1134. | 1.6 | 8 |
| 302 | Cigarette Smoking and ARDS After Blunt Trauma. <i>Chest</i> , 2020, 158, 1490-1498. | 0.4 | 8 |
| 303 | Functional characterization of novel rare <i>CYP2A6</i> variants and potential implications for clinical outcomes. <i>Clinical and Translational Science</i> , 2022, 15, 204-220. | 1.5 | 8 |
| 304 | Analyses of nicotine metabolism biomarker genetics stratified by sex in African and European Americans. <i>Scientific Reports</i> , 2021, 11, 19572. | 1.6 | 8 |
| 305 | Minoxidil-Associated Pleuropericardial Effusion. <i>Journal of General Internal Medicine</i> , 2016, 31, 1105-1105. | 1.3 | 7 |
| 306 | Nicotine biomarkers and rate of nicotine metabolism among cigarette smokers taking buprenorphine for opioid dependency. <i>Drug and Alcohol Dependence</i> , 2017, 178, 267-270. | 1.6 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 307 | Slower nicotine metabolism among postmenopausal Polish smokers. <i>Pharmacological Reports</i> , 2018, 70, 434-438. | 1.5 | 7 |
| 308 | Urine 4-(methylnitrosamino)-1-(3) pyridyl-1-butanol and cotinine in Alaska native postpartum women and neonates comparing smokers and smokeless tobacco users. <i>International Journal of Circumpolar Health</i> , 2018, 77, 1528125. | 0.5 | 7 |
| 309 | Black Light Smokers: How Nicotine Intake and Carcinogen Exposure Differ Across Various Biobehavioral Factors. <i>Journal of the National Medical Association</i> , 2019, 111, 509-520. | 0.6 | 7 |
| 310 | Butanediol Conversion to Gamma-Hydroxybutyrate Markedly Reduced by the Alcohol Dehydrogenase Blocker Fomepizole. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1196-1203. | 2.3 | 7 |
| 311 | Reductions in urinary metabolites of exposure to household air pollution in pregnant, rural Guatemalan women provided liquefied petroleum gas stoves. <i>Journal of Exposure Science and Environmental Epidemiology</i> , 2020, 30, 362-373. | 1.8 | 7 |
| 312 | Estimation of risk of neuropsychiatric adverse events from varenicline, bupropion and nicotine patch versus placebo: secondary analysis of results from the EAGLES trial using Bayes factors. <i>Addiction</i> , 2021, 116, 2816-2824. | 1.7 | 7 |
| 313 | Nicotine metabolite ratio: Comparison of the three urinary versions to the plasma version and nicotine clearance in three clinical studies. <i>Drug and Alcohol Dependence</i> , 2021, 223, 108708. | 1.6 | 7 |
| 314 | Nicotine Metabolite Ratio Is Associated With Lozenge Use But Not Quitting in Smokeless Tobacco Users. <i>Nicotine and Tobacco Research</i> , 2016, 18, 366-370. | 1.4 | 6 |
| 315 | Perceived risks and reasons to smoke cigarettes during pregnancy among Alaska native women. <i>Ethnicity and Health</i> , 2018, 23, 33-42. | 1.5 | 6 |
| 316 | Managing Cannabis Use in Patients With Cardiovascular Disease. <i>Canadian Journal of Cardiology</i> , 2019, 35, 138-141. | 0.8 | 6 |
| 317 | Effect of race and glucuronidation rates on the relationship between nicotine metabolite ratio and nicotine clearance. <i>Pharmacogenetics and Genomics</i> , 2021, 31, 97-107. | 0.7 | 6 |
| 318 | Effects of Marijuana Use on Smokers Switching to E-Cigarettes in a Randomized Clinical Trial. <i>Nicotine and Tobacco Research</i> , 2022, 24, 994-1002. | 1.4 | 6 |
| 319 | Tobacco toxicant exposure in cigarette smokers who use or do not use other tobacco products. <i>Drug and Alcohol Dependence</i> , 2017, 179, 330-336. | 1.6 | 5 |
| 320 | Relationship between skin melanin index and nicotine pharmacokinetics in African American smokers. <i>Drug and Alcohol Dependence</i> , 2019, 204, 107474. | 1.6 | 5 |
| 321 | E-cigarettes and dual nicotine replacement therapy for smoking cessation. <i>Lancet Respiratory Medicine</i> , 2020, 8, 7-8. | 5.2 | 5 |
| 322 | Relationships Between Race, Gender, and Spot Urine Levels of Biomarkers of Tobacco Exposure Vary Based on How Creatinine Is Handled in Analyses. <i>Nicotine and Tobacco Research</i> , 2020, 22, 2109-2113. | 1.4 | 5 |
| 323 | Peripheral Blood Flow Changes to Cutaneous and Muscular Beds in Response to Acute Hookah Smoking. <i>American Journal of Cardiology</i> , 2020, 125, 1725-1731. | 0.7 | 5 |
| 324 | Relations among cigarette dependence, e-cigarette dependence, and key dependence criteria among dual users of combustible and e-cigarettes. <i>Psychology of Addictive Behaviors</i> , 2022, 36, 100-108. | 1.4 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 325 | Response to Letter Regarding Article, "Efficacy and Safety of Varenicline for Smoking Cessation in Patients With Cardiovascular Disease: A Randomized Trial" Circulation, 2010, 122, . | 1.6 | 4 |
| 326 | Urinary NNAL in hookah smokers and non-smokers after attending a hookah social event in a hookah lounge or a private home. Regulatory Toxicology and Pharmacology, 2017, 89, 74-82. | 1.3 | 4 |
| 327 | Another Article About "Cigarettes: Why Should I Care?". Journal of the American Heart Association, 2018, 7, . | 1.6 | 4 |
| 328 | Effects of immediate versus gradual nicotine reduction in cigarettes on biomarkers of biological effects. Addiction, 2019, 114, 1824-1833. | 1.7 | 4 |
| 329 | Development and Piloting Testing of an Experimental Tobacco and Nicotine Product Marketplace. Nicotine and Tobacco Research, 2020, 22, 1230-1234. | 1.4 | 4 |
| 330 | Australian smokers'™ experiences and perceptions of recessed and firm filter cigarettes. Tobacco Control, 2021, 30, 660-667. | 1.8 | 4 |
| 331 | 3-Ethenylpyridine Measured in Urine of Active and Passive Smokers: A Promising Biomarker and Toxicological Implications. Chemical Research in Toxicology, 2021, 34, 1630-1639. | 1.7 | 4 |
| 332 | Cultural and demographic correlates of dual tobacco use in a sample of Alaska Native adults who smoke cigarettes. Tobacco Induced Diseases, 2020, 18, 55. | 0.3 | 4 |
| 333 | Chronic Disease Management Approach to Treating Tobacco Addiction. Archives of Internal Medicine, 2011, 171, 1907. | 4.3 | 3 |
| 334 | Biomarkers of Exposure to Nicotine and Tobacco-Specific Nitrosamines in Adolescent Blunt Users. Nicotine and Tobacco Research, 2020, 22, 1428-1429. | 1.4 | 3 |
| 335 | Effects of Nicotine Metabolic Rate on Cigarette Reinforcement. Nicotine and Tobacco Research, 2020, 22, 1419-1423. | 1.4 | 3 |
| 336 | Evidence of the effectiveness and safety of first-line smoking cessation pharmacotherapy. , 2021, , 97-117. | | 3 |
| 337 | Does sex alter the relationship between <i>CYP2B6</i> variation, hydroxybupropion concentration and bupropion-aided smoking cessation in African Americans? A moderated mediation analysis. Addiction, 2022, 117, 1715-1724. | 1.7 | 3 |
| 338 | Associations of Smokeless Tobacco Use With Cardiovascular Disease Risk: Insights From the Population Assessment of Tobacco and Health Study. Nicotine and Tobacco Research, 2022, 24, 1063-1070. | 1.4 | 3 |
| 339 | Stimulant drugs are associated with violent and penetrating trauma. American Journal of Emergency Medicine, 2019, 37, 645-650. | 0.7 | 2 |
| 340 | Loperamide associated torsades de pointes, in the setting of complete heart block at marginally supratherapeutic dosing (20mg/day). Clinical Toxicology, 2019, 57, 1123-1124. | 0.8 | 2 |
| 341 | Exposure to a Tobacco-Specific Carcinogen Among Adolescent Smokeless Tobacco Users in Rural California, United States. Nicotine and Tobacco Research, 2020, 22, 1764-1771. | 1.4 | 2 |
| 342 | The influence of nicotine metabolic rate on working memory over 6 hours of abstinence from nicotine. Pharmacology Biochemistry and Behavior, 2020, 188, 172836. | 1.3 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 343 | Comparison of smoking cessation rates of Quitline users in Korea between smokers of ultra-low nicotine yield cigarettes and other types of cigarette: a prospective study. <i>Addiction</i> , 2020, 115, 1745-1753. | 1.7 | 2 |
| 344 | Correlates of the nicotine metabolite ratio in Alaska Native people who smoke cigarettes.. <i>Experimental and Clinical Psychopharmacology</i> , 2022, 30, 359-364. | 1.3 | 2 |
| 345 | Neurobiology of Nicotine and Tobacco. , 2021, , . | | 2 |
| 346 | Pharmacogenetics of Nicotine Metabolism in Twins: Methods and Procedures. , 0, . | | 2 |
| 347 | Determination of 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone (NNK) arising from tobacco smoke in airborne particulate matter. <i>Environment International</i> , 2022, 158, 106992. | 4.8 | 2 |
| 348 | Tobacco-specific and combustion pollutants in settled house dust in Malta. , 2022, 1, . | | 2 |
| 349 | Maternal nicotine metabolism moderates the impact of maternal cigarette smoking on infant birth weight: A Collaborative Perinatal Project investigation. <i>Drug and Alcohol Dependence</i> , 2022, 233, 109358. | 1.6 | 2 |
| 350 | Diabetic Patients and Hepatic Drug Metabolism. <i>Clinical Pharmacology and Therapeutics</i> , 1989, 45, 695-694. | 2.3 | 1 |
| 351 | Recruitment best practices of a cardiovascular risk reduction randomised control trial in rural Alaska Native communities. <i>International Journal of Circumpolar Health</i> , 2020, 79, 1806639. | 0.5 | 1 |
| 352 | Evaluation of nicotine patch adherence measurement using self-report and saliva cotinine among abstainers in a smoking cessation trial. <i>Drug and Alcohol Dependence</i> , 2020, 210, 107967. | 1.6 | 1 |
| 353 | Disposition kinetics and effects of menthol. <i>Clinical Pharmacology and Therapeutics</i> , 1999, 66, 128-135. | 2.3 | 1 |
| 354 | Saliva cotinine levels as a function of collection method. , 1997, 92, 347. | | 1 |
| 355 | A Mobile Health Intervention for Adolescents Exposed to Secondhand Smoke: Pilot Feasibility and Efficacy Study. <i>JMIR Formative Research</i> , 2020, 4, e18583. | 0.7 | 1 |
| 356 | Relations among cigarette dependence, e-cigarette dependence, and key dependence criteria among dual users of combustible and e-cigarettes. <i>Psychology of Addictive Behaviors</i> , 2020, , . | 1.4 | 1 |
| 357 | Balfour etÂal. Respond. <i>American Journal of Public Health</i> , 2022, 112, e2-e3. | 1.5 | 1 |
| 358 | Early Changes in Puffing Intensity When Exclusively Using Open-Label Very Low Nicotine Content Cigarettes. <i>Nicotine and Tobacco Research</i> , 2022, , . | 1.4 | 1 |
| 359 | Minor Tobacco Alkaloids as Biomarkers to Distinguish Combusted Tobacco Use From Electronic Nicotine Delivery Systems Use. Two New Analytical Methods. <i>Frontiers in Chemistry</i> , 2022, 10, . | 1.8 | 1 |
| 360 | “You have the right to protect your health” Perceptions of Secondhand Smoke and Exposure Mitigation Strategies in Low-Income Patients With Heart Disease, San Francisco, 2011â€“2012. <i>Preventing Chronic Disease</i> , 2016, 13, E116. | 1.7 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 361 | A mixed effects model for analyzing area under the curve of longitudinally measured biomarkers with missing data. <i>Pharmaceutical Statistics</i> , 2021, 20, 1249-1264. | 0.7 | 0 |
| 362 | Secondhand smoke exposure in school children in Malta assessed through urinary biomarkers. <i>Environmental Research</i> , 2021, 204, 112405. | 3.7 | 0 |
| 363 | Balfour etÂal. Respond. <i>American Journal of Public Health</i> , 2022, 112, e5-e6. | 1.5 | 0 |
| 364 | Nicotine Addiction and Its Treatment. , 2022, , 297-341. | | 0 |